Navigation Links
Additional Data from the Qnexa Phase 3 Studies Presented at The Obesity Society 27th Annual Scientific Meeting
Date:10/29/2009

as recently completed phase 3 clinical trials for the treatment of obesity. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor, and in phase 2 development of Luramist(TM) for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE(R) (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on VIVUS' current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; reliance on sole source suppliers; limited sales and marketing efforts and dependence upon third parties; risks related to the development of innovative products; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical studies discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indicatio
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
2. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
3. First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
4. PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy
5. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
6. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
7. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
8. Pharmacopeia Announces Additional Positive Findings from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
9. Sulodexide Data Safety Monitoring Committee Completes Additional Review of Phase 3 Study Data
10. Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)
11. Paul Capital Healthcare Purchases Additional Royalty Interest in GlaxoSmithKlines Rotarix(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)...  When Ryan Rendino first felt the ... neck, he figured it was a muscle ... from weight lifting. But the ... A series of doctor appointments followed ... Michel Kliot, MD , a Northwestern ...
(Date:5/21/2015)... , May 21, 2015  Cardica, Inc. (Nasdaq: CRDC ... Greg Watson , the company,s vice president of operations, ... company,s common stock, at a per share exercise price of ... stock option was granted pursuant to Cardica, Inc.,s Inducement Plan, ... May 2015 under Rule 5653(c)(4) of the Nasdaq Global Market ...
(Date:5/21/2015)... 2015  Heidrick & Struggles (Nasdaq: HSII ), ... leadership consulting and culture shaping worldwide, ... practices announcing the addition of Tim Dietlin ... Dietlin has extensive life sciences and ... R&D, Medical and Commercial functions to increase productivity, drive ...
Breaking Medicine Technology:Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 2Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 3Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 4Cardica Announces New Employment Inducement Grant 2Heidrick Increases Healthcare and Life Sciences Expertise 2
... NogWorld LLC, a pioneer in mobile search technology, has launched DocNog, a mobile app ... , , ... "New and Noteworthy" section of Apple,s App Store .  Future versions of the ... , , ...
... BioSpecifics Technologies Corp. (Nasdaq: BSTC ), a biopharmaceutical ... strategic partner Auxilium Pharmaceuticals, Inc. has provided an update on XIAFLEX, ... treatment of Dupuytren,s contracture. , ... Auxilium announced that XIAFLEX sales to physicians were ...
Cached Medicine Technology:DocNog California Mobile App Automates Medical Provider Search 2BioSpecifics Technologies Corp. Announces Auxilium XIAFLEX® Update 2BioSpecifics Technologies Corp. Announces Auxilium XIAFLEX® Update 3
(Date:5/21/2015)... (PRWEB) May 21, 2015 Her popular Love ... the Hilton Hotel in San Gabriel on Saturday, May 23rd. ... over again from men and women who are unhappy in ... right partner." , "Many singles think that their biggest problem ... seeker would go from one relationship to another trying to ...
(Date:5/21/2015)... Nashville, TN (PRWEB) May 21, 2015 Ticket Down ... soccer match featuring USA vs. Guatemala on Friday, July ... time is now to become a fan of international soccer. The ... the world play on American soil is growing at a large ... worldwide teams have come to the USA to play in front ...
(Date:5/21/2015)... New York (PRWEB) May 21, 2015 ... Atmananda Yoga Studio and Sequence, is excited to ... Yoga Mat™, which was previously available for use exclusively ... Yoga Mat™ unique is that it's mathematically designed ... serious joint injuries and muscle strains, commonly experienced ...
(Date:5/21/2015)... Lawrenceville, NJ (PRWEB) May 21, 2015 ... scientific communication consultancy to the pharmaceutical and biotechnology industries ... access during the 2015 BIO International Convention in Philadelphia, ... Start Thinking Like a Payer,” will take place ... Dr. Laurie Smaldone , PharmApprove President and CSO, will ...
(Date:5/21/2015)... Angeles, CA (PRWEB) May 21, 2015 LOS ... Driver), the nation’s largest designated driver service, today announced the ... during the Memorial Day weekend. All new customers will receive ... and will be entered to win the grand prize of ... , Memorial Day weekend, traditionally viewed as the start of ...
Breaking Medicine News(10 mins):Health News:Bestselling Author Sheds Light on Why Modern Dating is Hurting People's Chances of Finding a Lasting Relationship 2Health News:USA vs. Guatemala Tickets: Ticket Down Slashes United States Men's Soccer Team (USMNT) vs. Guatemala Tickets at LP Field in Nashville on 7/3/15 2Health News:NY's Atmananda Yoga Studio Launches Its Patented "Alignment" Yoga Mat for Public Sale 2Health News:PharmApprove Panel at BIO Addresses Success in Drug Development Beyond Regulatory Approval 2Health News:PharmApprove Panel at BIO Addresses Success in Drug Development Beyond Regulatory Approval 3Health News:BeMyDD Announces Memorial Day Weekend Campaign to Decrease Drunk Driving Nationwide 2
... satisfaction in four key geographic regionsOAKLAND, Calif., April ... members in four geographic regions rated the organization,s ... J.D. Power and Associates 2009 National Health Insurance ... California and the Northwest. These plans serve ...
... Risk factor is one women can do little about, experts ... researchers have known that breast density is almost as important ... But now they,re discovering how the density of a woman,s ... cancer treatment and whether her cancer will recur. , The ...
... Rainbow SET(R) Pulse CO-Oximetry(TM) Could Generate Nearly $500,000 ... IRVINE, Calif., April 16, Masimo (Nasdaq: ... Measure-Through Motion and Low-Perfusion pulse oximetry, announced today ... and technology services, has released a study showing ...
... Discoveries About Attention And Memory, Joins World,s ... NeuroFocus, the world leader in the rapidly-growing ... brainwave-based measurements for market research purposes--announced that ... Partner in the company,s Consulting Practice.Dr. Smith ...
... Gold Standard Status for Ulcerative Colitis in 2012, ... Mass., April 16 Decision Resources, one of ... pharmaceutical and healthcare issues, finds that surveyed gastroenterologists ... as the attribute that most influences their prescribing ...
... Next Generation Network magazine has named Zultys as a recipient of the ... , ... Sunnyvale, CA (PRWEB) April 15, 2009 -- Zultys Inc. ... Zultys as a recipient of the First Annual NGN Leadership Award for ...
Cached Medicine News:Health News:Kaiser Permanente Receives Top Marks in 2009 J.D. Power and Associates Study 2Health News:Kaiser Permanente Receives Top Marks in 2009 J.D. Power and Associates Study 3Health News:Kaiser Permanente Receives Top Marks in 2009 J.D. Power and Associates Study 4Health News:Dense Breasts Complicate Testing and Treatment 2Health News:Dense Breasts Complicate Testing and Treatment 3Health News:Capgemini Releases New Study on Financial Impact of Masimo Noninvasive and Continuous Hemoglobin (SpHb(TM)) 2Health News:Capgemini Releases New Study on Financial Impact of Masimo Noninvasive and Continuous Hemoglobin (SpHb(TM)) 3Health News:Capgemini Releases New Study on Financial Impact of Masimo Noninvasive and Continuous Hemoglobin (SpHb(TM)) 4Health News:NeuroFocus Appoints Dr. Michael Smith as Partner in Consulting Practice 2Health News:For Ulcerative Colitis, Surveyed Experts Indicate That Corticosteroids Have Advantages Over Remicade in the Induction of Remission 2Health News:For Ulcerative Colitis, Surveyed Experts Indicate That Corticosteroids Have Advantages Over Remicade in the Induction of Remission 3Health News:Zultys Inc. Receives 2009 NGN Leadership Award from NGN Magazine 2Health News:Zultys Inc. Receives 2009 NGN Leadership Award from NGN Magazine 3Health News:Zultys Inc. Receives 2009 NGN Leadership Award from NGN Magazine 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: